EquitySector - HealthcareVery High Risk
Regular
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹1,150 Cr
Expense Ratio
2.22%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.85%
+12.48% (Cat Avg.)
3 Years
+19.52%
+18.71% (Cat Avg.)
5 Years
+22.98%
+23.12% (Cat Avg.)
10 Years
+11.10%
+13.23% (Cat Avg.)
Since Inception
+14.75%
— (Cat Avg.)
Equity | ₹1,124.46 Cr | 97.74% |
Others | ₹25.97 Cr | 2.26% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹126.44 Cr | 10.99% |
Cipla Ltd | Equity | ₹68.78 Cr | 5.98% |
Dr Reddy's Laboratories Ltd | Equity | ₹57.24 Cr | 4.98% |
Ajanta Pharma Ltd | Equity | ₹50.33 Cr | 4.38% |
Glenmark Pharmaceuticals Ltd | Equity | ₹44.95 Cr | 3.91% |
Procter & Gamble Health Ltd | Equity | ₹39.83 Cr | 3.46% |
Apollo Hospitals Enterprise Ltd | Equity | ₹38.32 Cr | 3.33% |
Gland Pharma Ltd | Equity | ₹36.67 Cr | 3.19% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹36.42 Cr | 3.17% |
Fortis Healthcare Ltd | Equity | ₹35.7 Cr | 3.10% |
Divi's Laboratories Ltd | Equity | ₹34.29 Cr | 2.98% |
Alkem Laboratories Ltd | Equity | ₹31.91 Cr | 2.77% |
Suven Pharmaceuticals Ltd | Equity | ₹30.9 Cr | 2.69% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹30.7 Cr | 2.67% |
Aurobindo Pharma Ltd | Equity | ₹29.3 Cr | 2.55% |
Caplin Point Laboratories Ltd | Equity | ₹26.97 Cr | 2.34% |
Zydus Lifesciences Ltd | Equity | ₹26 Cr | 2.26% |
Emcure Pharmaceuticals Ltd | Equity | ₹24.57 Cr | 2.14% |
Net Current Assets | Cash | ₹24.53 Cr | 2.13% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹24.05 Cr | 2.09% |
Torrent Pharmaceuticals Ltd | Equity | ₹21.64 Cr | 1.88% |
Jupiter Life Line Hospitals Ltd | Equity | ₹21.18 Cr | 1.84% |
Global Health Ltd | Equity | ₹20.79 Cr | 1.81% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.26 Cr | 1.76% |
Metropolis Healthcare Ltd | Equity | ₹17.97 Cr | 1.56% |
Windlas Biotech Ltd | Equity | ₹16.81 Cr | 1.46% |
Sequent Scientific Ltd | Equity | ₹16.51 Cr | 1.44% |
Marksans Pharma Ltd | Equity | ₹16.43 Cr | 1.43% |
Sai Life Sciences Ltd | Equity | ₹16.15 Cr | 1.40% |
Pfizer Ltd | Equity | ₹15.67 Cr | 1.36% |
Vijaya Diagnostic Centre Ltd | Equity | ₹15.54 Cr | 1.35% |
Ami Organics Ltd | Equity | ₹15.49 Cr | 1.35% |
Ipca Laboratories Ltd | Equity | ₹14.43 Cr | 1.25% |
Syngene International Ltd | Equity | ₹13.44 Cr | 1.17% |
Concord Biotech Ltd | Equity | ₹11.94 Cr | 1.04% |
Alembic Pharmaceuticals Ltd | Equity | ₹11.32 Cr | 0.98% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.15 Cr | 0.97% |
Indegene Ltd | Equity | ₹10.93 Cr | 0.95% |
Orchid Pharma Ltd | Equity | ₹8.99 Cr | 0.78% |
Laxmi Dental Ltd | Equity | ₹8.92 Cr | 0.78% |
Rainbow Childrens Medicare Ltd | Equity | ₹8.81 Cr | 0.77% |
Jubilant Pharmova Ltd | Equity | ₹8.73 Cr | 0.76% |
Poly Medicure Ltd | Equity | ₹8 Cr | 0.70% |
364 Days T - Bill- 06/02/2025 | Bond - Gov't/Treasury | ₹1.3 Cr | 0.11% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.14 Cr | 0.01% |
Large Cap Stocks
29.07%
Mid Cap Stocks
24.22%
Small Cap Stocks
43.68%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,108.97 Cr | 96.40% |
Basic Materials | ₹15.49 Cr | 1.35% |
Standard Deviation
This fund
15.78%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.84
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.22% | Exit Load 1.00% | Fund Size ₹1,150 Cr | Age 25 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹3,20,185 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹1,150 Cr
Expense Ratio
2.22%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.85%
+12.48% (Cat Avg.)
3 Years
+19.52%
+18.71% (Cat Avg.)
5 Years
+22.98%
+23.12% (Cat Avg.)
10 Years
+11.10%
+13.23% (Cat Avg.)
Since Inception
+14.75%
— (Cat Avg.)
Equity | ₹1,124.46 Cr | 97.74% |
Others | ₹25.97 Cr | 2.26% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹126.44 Cr | 10.99% |
Cipla Ltd | Equity | ₹68.78 Cr | 5.98% |
Dr Reddy's Laboratories Ltd | Equity | ₹57.24 Cr | 4.98% |
Ajanta Pharma Ltd | Equity | ₹50.33 Cr | 4.38% |
Glenmark Pharmaceuticals Ltd | Equity | ₹44.95 Cr | 3.91% |
Procter & Gamble Health Ltd | Equity | ₹39.83 Cr | 3.46% |
Apollo Hospitals Enterprise Ltd | Equity | ₹38.32 Cr | 3.33% |
Gland Pharma Ltd | Equity | ₹36.67 Cr | 3.19% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹36.42 Cr | 3.17% |
Fortis Healthcare Ltd | Equity | ₹35.7 Cr | 3.10% |
Divi's Laboratories Ltd | Equity | ₹34.29 Cr | 2.98% |
Alkem Laboratories Ltd | Equity | ₹31.91 Cr | 2.77% |
Suven Pharmaceuticals Ltd | Equity | ₹30.9 Cr | 2.69% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹30.7 Cr | 2.67% |
Aurobindo Pharma Ltd | Equity | ₹29.3 Cr | 2.55% |
Caplin Point Laboratories Ltd | Equity | ₹26.97 Cr | 2.34% |
Zydus Lifesciences Ltd | Equity | ₹26 Cr | 2.26% |
Emcure Pharmaceuticals Ltd | Equity | ₹24.57 Cr | 2.14% |
Net Current Assets | Cash | ₹24.53 Cr | 2.13% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹24.05 Cr | 2.09% |
Torrent Pharmaceuticals Ltd | Equity | ₹21.64 Cr | 1.88% |
Jupiter Life Line Hospitals Ltd | Equity | ₹21.18 Cr | 1.84% |
Global Health Ltd | Equity | ₹20.79 Cr | 1.81% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.26 Cr | 1.76% |
Metropolis Healthcare Ltd | Equity | ₹17.97 Cr | 1.56% |
Windlas Biotech Ltd | Equity | ₹16.81 Cr | 1.46% |
Sequent Scientific Ltd | Equity | ₹16.51 Cr | 1.44% |
Marksans Pharma Ltd | Equity | ₹16.43 Cr | 1.43% |
Sai Life Sciences Ltd | Equity | ₹16.15 Cr | 1.40% |
Pfizer Ltd | Equity | ₹15.67 Cr | 1.36% |
Vijaya Diagnostic Centre Ltd | Equity | ₹15.54 Cr | 1.35% |
Ami Organics Ltd | Equity | ₹15.49 Cr | 1.35% |
Ipca Laboratories Ltd | Equity | ₹14.43 Cr | 1.25% |
Syngene International Ltd | Equity | ₹13.44 Cr | 1.17% |
Concord Biotech Ltd | Equity | ₹11.94 Cr | 1.04% |
Alembic Pharmaceuticals Ltd | Equity | ₹11.32 Cr | 0.98% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.15 Cr | 0.97% |
Indegene Ltd | Equity | ₹10.93 Cr | 0.95% |
Orchid Pharma Ltd | Equity | ₹8.99 Cr | 0.78% |
Laxmi Dental Ltd | Equity | ₹8.92 Cr | 0.78% |
Rainbow Childrens Medicare Ltd | Equity | ₹8.81 Cr | 0.77% |
Jubilant Pharmova Ltd | Equity | ₹8.73 Cr | 0.76% |
Poly Medicure Ltd | Equity | ₹8 Cr | 0.70% |
364 Days T - Bill- 06/02/2025 | Bond - Gov't/Treasury | ₹1.3 Cr | 0.11% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.14 Cr | 0.01% |
Large Cap Stocks
29.07%
Mid Cap Stocks
24.22%
Small Cap Stocks
43.68%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,108.97 Cr | 96.40% |
Basic Materials | ₹15.49 Cr | 1.35% |
Standard Deviation
This fund
15.78%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.84
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.22% | Exit Load 1.00% | Fund Size ₹1,150 Cr | Age 25 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹3,20,185 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments